RNA Clinical Trials Videos

  1. How Is mRNA "Shaking Up" Our Regulatory Interactions & Operations Today? 5/10/2024

    The Advancing RNA Live panelists share several inconsistencies they’ve encountered working with global regulators, as well as on which aspects they’re seeing regulatory agencies applying greater scrutiny in mRNA development today.

  2. RNA-Based Therapeutics With Nutcracker Therapeutics' Dr. Geoff Nosrati 11/21/2022

    Nutcracker Therapeutics is a preclinical biopharma company developing multimodal RNA-based therapeutics for HPV-driven tumors, T-cell lymphoma, and Genitourinary tumors. On this episode of the Business of Biotech, Chief Business Officer Geoff Nosrati, Ph.D. offers a comprehensive view of the RNA-based therapeutics landscape and sheds light on what he perceives as an advantageous position at Nutcracker — the capacity to manufacture RNA in-house. If you're curious about the expanding science behind RNA-based therapeutics and their application in biotech, this conversation with a scientist-turned-chief business officer (Nosrati earned his Ph.D. in Biochemistry and Molecular Biology) is a can't-miss episode.

  3. Who's In Charge? How To Ensure Effective Trial Oversight, Leadership 3/19/2025

    Gain valuable insights into the role of sponsor-side Clinical Operations leadership, the risks of over-relying on CROs, and key strategies for fostering collaboration between sponsors and partners.

  4. A Deeper Dive On Mitigating Financial Risk Before Selecting A Vendor 1/23/2024

    In part two of this webinar series, presenters focus on avoiding potential risks, such as unexpected budget changes and unplanned change orders, that could jeopardize the success of a clinical trial.

  5. Development And Regulatory Strategy For US And China 9/22/2022

    This webinar discusses the expansion of International Market for Ensartini and RNAi Therapeutics in Oncology, from Skin Cancers to Liver Cancers.

  6. Translation Of RNA Nanomedicines From Design To Clinical 4/14/2022

    mRNA therapeutics are applicable to cancer immunotherapies, infectious diseases, and other indications that require protein replacement therapy or antibodies.

  7. PepGen's SVP Head Of Clinical Development On Delivery Of Oligonucleotide Therapies 10/27/2022

    PepGen, a Cambridge, MA-based biotech, is advancing oligonucleotide therapeutics with the goal of transforming the treatment of severe neuromuscular and neurologic diseases. SVP Head of Clinical Development Dr. Michelle Mellion explains PepGen's trial of PGN-EDO51, the company’s lead product candidate for the treatment of DMD patients whose mutations are amenable to an exon 51 skipping approach. She also explains how the delivery of oligonucleotide therapies differ from other techniques in genetic medicine, and much more.

  8. Obesity, From The Bench To The Bedside 12/2/2025

    Watch as experts in a multidisciplinary panel discuss the biological and clinical burden of obesity, emerging innovations in biotech and clinical practice, and patient experiences and societal factors.

  9. Achieving mRNA-LNP Delivery Beyond The Liver 11/28/2022

    In this segment, Russell Johnson, VP Formulation Research for RVAC Medicines, and Aalok Shah, Director of Formulation & Drug Delivery, Strand Therapeutics, discuss which ongoing industry efforts to improve LNPs and the RNA/mRNA cargo they're watching closely that could help the RNA industry move beyond hepatic delivery.

  10. Accelerating Clinical Development In China & The US 9/22/2022

    Discover how the clinical research bridge between China and the US supports accelerated clinical development from early to late phase trials while ensuring the inclusion of MRCT data packages in future regulatory applications.